scholarly journals Microvesicles Derived from Inflammation-Challenged Endothelial Cells Modulate Vascular Smooth Muscle Cell Functions

2017 ◽  
Vol 7 ◽  
Author(s):  
Qunwen Pan ◽  
Hua Liu ◽  
Chunyan Zheng ◽  
Yuhui Zhao ◽  
Xiaorong Liao ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Smooth Muscle ◽  
Vascular Smooth Muscle ◽  
Smooth Muscle Cell ◽  
Muscle Cell ◽  
Vascular Smooth Muscle Cell ◽  
Cell Functions

scholarly journals LKB1 in endothelial cells is required for angiogenesis and TGF -mediated vascular smooth muscle cell recruitment

Development ◽  
2008 ◽  
Vol 135 (13) ◽  
pp. 2331-2338 ◽  
Author(s):  
A. Londesborough ◽  
K. Vaahtomeri ◽  
M. Tiainen ◽  
P. Katajisto ◽  
N. Ekman ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Smooth Muscle ◽  
Vascular Smooth Muscle ◽  
Smooth Muscle Cell ◽  
Muscle Cell ◽  
Vascular Smooth Muscle Cell ◽  
Cell Recruitment

scholarly journals CD73 regulates vascular smooth muscle cell functions and facilitates atherosclerotic plaque formation

IUBMB Life ◽  
2015 ◽  
Vol 67 (11) ◽  
pp. 853-860 ◽  
Author(s):  
Jiayin Yang ◽  
Rongrong Jian ◽  
Jiangang Yu ◽  
Xiuling Zhi ◽  
Xiaohong Liao ◽  
...  
Keyword(s):  
Smooth Muscle ◽  
Vascular Smooth Muscle ◽  
Smooth Muscle Cell ◽  
Muscle Cell ◽  
Vascular Smooth Muscle Cell ◽  
Atherosclerotic Plaque ◽  
Plaque Formation ◽  
Cell Functions ◽  
Atherosclerotic Plaque Formation

scholarly journals Cilostazol inhibits uremic toxin–induced vascular smooth muscle cell dysfunction: role of Axl signaling

2017 ◽  
Vol 312 (3) ◽  
pp. F398-F406 ◽  
Author(s):  
Chien-Hsing Lee ◽  
Yi-Jen Hung ◽  
Yi-Shing Shieh ◽  
Chu-Yen Chien ◽  
Yu-Juei Hsu ◽  
...  
Keyword(s):  
Gene Expression ◽  
Smooth Muscle ◽  
Vascular Smooth Muscle ◽  
Smooth Muscle Cell ◽  
Muscle Cell ◽  
Vascular Smooth Muscle Cell ◽  
Uremic Toxin ◽  
Cell Functions

Chronic kidney disease (CKD) is associated with increased cardiovascular mortality, and vascular smooth muscle cell (VSMC) dysfunction plays a pivotal role in uremic atherosclerosis. Axl signaling is involved in vascular injury and is highly expressed in VSMCs. Recent reports have shown that cilostazol, a phosphodiesterase type 3 inhibitor (PDE3), can regulate various stages of the atherosclerotic process. However, the role of cilostazol in uremic vasculopathy remains unclear. This study aimed to identify the effect of cilostazol in VSMCs in the experimental CKD and to investigate whether the regulatory mechanism occurs through Axl signaling. We investigated the effect of P-cresol and cilostazol on Axl signaling in A7r5 rat VSMCs and the rat and human CKD models. From the in vivo CKD rats and patients, aortic tissue exhibited significantly decreased Axl expression after cilostazol treatment. P-cresol increased Axl, proliferating of cell nuclear antigen (PCNA), focal adhesion kinase (FAK), and matrix metalloproteinase-2 (MMP-2) expressions, decreased caspase-3 expression, and was accompanied by increased cell viability and migration. Cilostazol significantly reversed P-cresol-induced Axl, downstream gene expressions, and cell functions. Along with the increased Axl expression, P-cresol activated PLCγ, Akt, and ERK phosphorylation and cilostazol significantly suppressed the effect of P-cresol. Axl knockdown significantly reversed the expressions of P-cresol-induced Axl-related gene expression and cell functions. Cilostazol with Axl knockdown have additive changes in downstream gene expression and cell functions in P-cresol culture. Both in vitro and in vivo experimental CKD models elucidate a new signal transduction of cilostazol-mediated protection against uremic toxin-related VSMCs dysfunction and highlight the involvement of the Axl signaling and downstream pathways.

Sign in / Sign up

Export Citation Format

Share Document